Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Analysis of the impact of eliminating bolus 5-fluorouracil in metastatic colorectal cancer.
Authors
Chengwei Peng
NYU, New York, NY;
Chengwei Peng , Saad Saffo , Michael Shusterman , Daniel Jacob Becker , Jordan Berlin , Paul Eliezer Oberstein , Anil Nagar , Shun Yu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 59)
DOI
10.1200/JCO.2023.41.4_suppl.59
Abstract #
59
Poster Bd #
C14
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world analysis of irinotecan (iri) with or without fluorouracil (5FU) in the second line treatment (2L) of metastatic colorectal cancer (mCRC).
First Author: Robert William Lentz
Poster
2023 ASCO Annual Meeting
Impact of sex on the efficacy of first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus Y90-radioembolization in patients with metastatic colorectal cancer: An exploratory, retrospective analysis of the phase III SIRFLOX trial.
First Author: Kathrin Heinrich
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.
First Author: Seiichiro Mitani